nach oben

Erschienen in:

01.11.2018 | Clinical study

Malignant melanoma in natalizumab recipients with MS

Erschienen in: Reactions Weekly | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Excerpt

In patients with multiple sclerosis (MS), treatment with natalizumab appears to be associated with an increased risk of malignant melanoma (MM), according to the results of a study evaluating three databases reported in the Journal of the American Academy of Dermatology. …

Kelm RC, et al. Melanoma subsequent to natalizumab exposure: A report from the RADAR (Research on Adverse Drug events And Reports) Program. Journal of the American Academy of Dermatology : 2 Nov 2018. Available from: URL: http://doi.org/10.1016/j.jaad.2018.10.052

Titel: Malignant melanoma in natalizumab recipients with MS
Publikationsdatum: 01.11.2018
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2018
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-018-54273-2

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Malignant melanoma in natalizumab recipients with MS

Excerpt

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2018

Dydrogesterone/estradiol

Immune globulin

Dimethyl fumarate overdose

Thioctic acid overdose

Dupilumab

Quetiapine